Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple sexually transmitted infections from a single sample. | The company’s cobas ...
In an Ontario Court of Justice in St. Catharines on Friday a 26-year-old woman pleaded guilty to a charge of sexual ...
Metro Detroit has earned the dubious distinction of leading the country with the highest rate of sexually transmitted ...
SCHD said that the partnership will allow expanded clinical services, enabling the health department to provide HIF and ...
The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...
More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old ...
A new strain of gonorrhea has emerged, causing significant concern among health professionals due to its resistance to traditional treatments. This sexually ...
The World Health Organization (WHO) recently released new estimates suggesting around 846 million people aged between 15 and ...
US FDA grants 510(k) clearance and CLIA waiver to Roche’s cobas liat sexually transmitted infection multiplex assay panels: Basel Thursday, January 23, 2025, 09:00 Hrs [IST] Roc ...
HPV can cause a variety of cancers, including cervical. New mortality data for women under 25 point to the success of the HPV vaccine.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver ...
"The vast majority of cervical cancers are actually caused by the HPV," said Dr. Matthew Oliver who specializes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback